文献速递痛风与晶体性关节病

糖尿病合并痛风患者别嘌醇的依从性、持续性与使用模式:基于人群的回顾性队列分析

Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: A retrospective, population-based cohort analysis.
PubMed 文献 · Semin Arthritis Rheum · 2021-09-16

该回顾性队列研究纳入22,056例66岁以上糖尿病合并痛风且新开具别嘌醇的个体,随访最长3年,评估别嘌醇使用模式、非持续性预测因素及与痛风严重程度指标的关系。41.2%患者为非持续性,女性、痴呆及既往一年痛风门诊就诊与非持续性风险升高相关;中断者和停药者较持续使用者有更严重的痛风指标,包括更常被开具泼尼松。

要点

  • 糖尿病合并痛风患者中别嘌醇非持续性常见,占41.2%。
  • 女性、痴呆及既往一年痛风门诊就诊与非持续性风险升高相关。
  • 中断或停用别嘌醇者较持续使用者更常被开具泼尼松。

核心结论

  • 糖尿病合并痛风患者中别嘌醇非持续性和中断频繁,且与泼尼松处方相关。
  • 别嘌醇依从性欠佳可能增加痛风并发症风险,并可能通过更多泼尼松使用影响血糖控制而增加糖尿病并发症风险。

研究设计与样本

  • 回顾性、基于人群的队列分析,纳入66岁以上糖尿病合并痛风且新开具别嘌醇的个体,随访最长3年。
  • 共纳入22,056例个体,其中17,410例有3年随访数据。

主要发现

  • 9,092例(41.2%)为非持续性;12,964例(58.8%)为持续使用者,4,618例(20.9%)为中断者,4,474例(20.3%)为停药者。
  • 非持续性风险升高与女性(HR 1.28,95%CI 1.23-1.33)、痴呆(HR 1.23,95%CI 1.11-1.35)及既往一年痛风门诊就诊(HR 1.19,95%CI 1.09-1.29)相关。
  • 中断者和停药者较持续使用者有更严重的痛风指标,包括更常被开具泼尼松。

关键数值与推荐

  • 别嘌醇使用模式分为持续使用者(随访期间持续使用)、中断者(非持续但后续恢复)和停药者(非持续且未再恢复)。
  • 非持续性定义为未再开具处方并考虑宽限期。

临床怎么用

  • 对糖尿病合并痛风患者应关注别嘌醇持续使用情况,识别女性、痴呆及近期痛风门诊就诊等高危非持续性人群。
  • 别嘌醇中断或停用可能与更严重的痛风及更多泼尼松使用相关,需加强用药管理和随访。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There has been growing interest in the potential role for allopurinol to reduce cardiovascular events in people with diabetes. While adherence to allopurinol is poor in those with gout, our aim was to characterize persistence, patterns of use, and predictors of allopurinol use in a population-based cohort of individuals with diabetes and gout. METHODS: Individuals with diabetes older than 66 (thus eligible for prescription medication coverage) and newly prescribed allopurinol were followed for up to three years in a retrospective cohort study. Allopurinol use patterns were categorized as adherer (used continuously throughout follow-up), interrupter (non-persistent but subsequently resumed), or discontinuer (non-persistent with no subsequent resumption). Main outcomes were allopurinol non-persistence (no subsequent prescription accounting for a grace period), and indicators of gout severity throughout follow-up (prescriptions for prednisone or colchicine, outpatient gout visits, hospitalization/emergency department visits for gout). Outcome frequencies were determined, a multivariable Cox proportional hazards model evaluated associations between predictors and non-persistence, and zero-inflated negative binomial (ZINB) models evaluated associations between allopurinol use pattern and indicators of gout severity. RESULTS: 22,056 individuals were followed for a maximum of 3.0 years (17,410 with 3 years of follow-up). 9092 (41.2%) were non-persistent with allopurinol. Higher risks of non-persistence were associated with female sex (HR, 95% CI: 1.28, 1.23-1.33), dementia (1.23, 1.11-1.35), and an outpatient visit for gout in the prior year (1.19, 1.09-1.29). There were 12,964 (58.8%) allopurinol adherers, 4618 interrupters (20.9%), and 4474 (20.3%) discontinuers. Allopurinol interrupters and discontinuers had indicators of more severe gout over time compared to adherers, including greater odds of being prescribed prednisone. CONCLUSION: Allopurinol non-persistence and interruptions were frequent in individuals with diabetes and gout and were associated with prescriptions for prednisone. Suboptimal allopurinol adherence may not only increase the risk of gout complications in this population but also potentially diabetes complications through greater prednisone use and its negative effects on glycemic control.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Weisman A, Tomlinson GA, Lipscombe LL, et al. Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: A retrospective, population-based cohort analysis. Semin Arthritis Rheum. 2021. PMID: 34555659. doi:10.1016/j.semarthrit.2021.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。